Towards targeting the lymphoma microenvironment

针对淋巴瘤微环境

基本信息

  • 批准号:
    10704574
  • 负责人:
  • 金额:
    $ 90.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-01 至 2027-08-31
  • 项目状态:
    未结题

项目摘要

Towards Targeting the Follicular Lymphoma Microenvironment Follicular lymphoma (FL) is the second most common and still incurable form of B cell lymphoma. FL is a slow growing cancer that shows a unique dependence on a supportive microenvironment. The supportive niche also affects FL therapies. For example, inhibitors of BTK, PI3K, or BCL2 show exciting activity against aggressive lymphomas and chronic leukemia, but they have little activity against indolent FLs. We speculate that the FL microenvironment protects and sustains the malignant B cells and contributes to FL development, progression, and resistance to therapy. Conversely, we propose that disrupting interactions in the FL niche will be especially effective against FL. Our hypothesis is based on prior work by others and our own work on immune receptor mutations in FL (e.g. TNFSRF14 and EphA7) have revealed cell-cell interactions as key drivers and sustainers of FL biology. My lab has made major contributions to our understanding of the biology and genetics of FL. We built an accurate mouse model of FL and we and others have used this model to interpret the biological function of the most common FL drivers. For example, we reported on the role of epigenetic driver mutations in KMT2D, CREBBP, EZH2, we investigated FL cell metabolism, cell cycle control, aberrant mRNA translation, and the outstanding importance of immune receptors (e.g. TNFSRF14, b2M, EphA7) in FL biology. This work has been reported in an extensive series of high-impact publications. It has also led to several patent filings that protect experimental lymphoma therapies. We now propose a systematic assessment of the cellular composition of the FL microenvironment using cutting edge single-cell RNA sequencing on murine and human FLs. We want to understand how tumor genotype, indolent versus transformed disease stage, and therapy (esp. checkpoint inhibition) shapes the FL niche. We use single cell data to formulate specific hypotheses concerning cell-cell interactions and we use genetic and molecular biology tools to explore underlying mechanisms. Our goal is to identify opportunities to disrupt the supportive niche and to exploit this for new therapies. We have already had some success in this regard, and we engineered bi-functional antibodies and modified CAR-T cells that target interactions between malignant B cells and supportive niche elements. !
针对滤泡性淋巴瘤微环境的研究

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Rapamycin-Induced Feedback Activation of eIF4E-EIF4A Dependent mRNA Translation in Pancreatic Cancer.
  • DOI:
    10.3390/cancers15051444
  • 发表时间:
    2023-02-24
  • 期刊:
  • 影响因子:
    5.2
  • 作者:
  • 通讯作者:
A Rapid Translational Immune Response Program in CD8 Memory T Lymphocytes.
  • DOI:
    10.4049/jimmunol.2100537
  • 发表时间:
    2022-09-15
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    Salloum, Darin;Singh, Kamini;Davidson, Natalie R.;Cao, Linlin;Kuo, David;Sanghvi, Viraj R.;Jiang, Man;Lafoz, Maria Tello;Viale, Agnes;Ratsch, Gunnar;Wendel, Hans-Guido
  • 通讯作者:
    Wendel, Hans-Guido
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hans-Guido Wendel其他文献

Hans-Guido Wendel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hans-Guido Wendel', 18)}}的其他基金

Towards targeting the lymphoma microenvironment
针对淋巴瘤微环境
  • 批准号:
    10248398
  • 财政年份:
    2020
  • 资助金额:
    $ 90.86万
  • 项目类别:
Towards targeting the lymphoma microenvironment
针对淋巴瘤微环境
  • 批准号:
    10469578
  • 财政年份:
    2020
  • 资助金额:
    $ 90.86万
  • 项目类别:
Towards The Chemotherapy-Free Treatment of Follicular Lymphoma
走向滤泡性淋巴瘤的无化疗治疗
  • 批准号:
    8670250
  • 财政年份:
    2014
  • 资助金额:
    $ 90.86万
  • 项目类别:
Towards The Chemotherapy-Free Treatment of Follicular Lymphoma
走向滤泡性淋巴瘤的无化疗治疗
  • 批准号:
    8845530
  • 财政年份:
    2014
  • 资助金额:
    $ 90.86万
  • 项目类别:
Towards The Chemotherapy-Free Treatment of Follicular Lymphoma
走向滤泡性淋巴瘤的无化疗治疗
  • 批准号:
    9055665
  • 财政年份:
    2014
  • 资助金额:
    $ 90.86万
  • 项目类别:
STRUCTURE FUNCTION STUDY OF A NOVEL TUMOR SUPPRESSOR, EPHA
新型肿瘤抑制因子 EPHA 的结构功能研究
  • 批准号:
    8361588
  • 财政年份:
    2011
  • 资助金额:
    $ 90.86万
  • 项目类别:
The contribution of protein translation to tumorigenesis
蛋白质翻译对肿瘤发生的贡献
  • 批准号:
    8595293
  • 财政年份:
    2010
  • 资助金额:
    $ 90.86万
  • 项目类别:
The contribution of protein translation to tumorigenesis
蛋白质翻译对肿瘤发生的贡献
  • 批准号:
    8035418
  • 财政年份:
    2010
  • 资助金额:
    $ 90.86万
  • 项目类别:
The contribution of protein translation to tumorigenesis
蛋白质翻译对肿瘤发生的贡献
  • 批准号:
    8408806
  • 财政年份:
    2010
  • 资助金额:
    $ 90.86万
  • 项目类别:
The contribution of protein translation to tumorigenesis
蛋白质翻译对肿瘤发生的贡献
  • 批准号:
    8207977
  • 财政年份:
    2010
  • 资助金额:
    $ 90.86万
  • 项目类别:

相似海外基金

Roles of immune cells derived from clonal hematopoiesis in B-cell lymphomas
克隆造血来源的免疫细胞在 B 细胞淋巴瘤中的作用
  • 批准号:
    24K19213
  • 财政年份:
    2024
  • 资助金额:
    $ 90.86万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Identification of novel biomarkers for EBV-associated B-cell lymphomas arising in the oral cavity
口腔中出现的 EBV 相关 B 细胞淋巴瘤的新型生物标志物的鉴定
  • 批准号:
    23K15982
  • 财政年份:
    2023
  • 资助金额:
    $ 90.86万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Chromunities Drive Transcriptional Reprogramming in Humoral Immunity and B-cell Lymphomas
染色体驱动体液免疫和 B 细胞淋巴瘤中的转录重编程
  • 批准号:
    10606730
  • 财政年份:
    2023
  • 资助金额:
    $ 90.86万
  • 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
  • 批准号:
    10566833
  • 财政年份:
    2023
  • 资助金额:
    $ 90.86万
  • 项目类别:
Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-cell Lymphomas
通过合作进行治愈:利用合作团体对抗慢性淋巴细胞白血病和 B 细胞淋巴瘤
  • 批准号:
    10987699
  • 财政年份:
    2023
  • 资助金额:
    $ 90.86万
  • 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
  • 批准号:
    10541285
  • 财政年份:
    2022
  • 资助金额:
    $ 90.86万
  • 项目类别:
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
  • 批准号:
    10540952
  • 财政年份:
    2022
  • 资助金额:
    $ 90.86万
  • 项目类别:
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
HIV 感染者 EBV 阳性弥漫性大 B 细胞淋巴瘤的合成致死靶向
  • 批准号:
    10703446
  • 财政年份:
    2022
  • 资助金额:
    $ 90.86万
  • 项目类别:
Therapeutic potential of novel antibody-oligonucleotide conjugate for intractable B-cell lymphomas
新型抗体-寡核苷酸缀合物治疗难治性 B 细胞淋巴瘤的潜力
  • 批准号:
    22K08497
  • 财政年份:
    2022
  • 资助金额:
    $ 90.86万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of Epstein-Barr virus LMP2A protein in maintaining oncogenic IgM signaling in EBV+ B cell lymphomas
Epstein-Barr病毒LMP2A蛋白在维持EBV B细胞淋巴瘤中致癌IgM信号传导中的作用
  • 批准号:
    10707312
  • 财政年份:
    2022
  • 资助金额:
    $ 90.86万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了